glp-1 weight loss clinical trials GLP1 agonists: current and future landscape of for patients with metabolic dysfunction Study finds GLP-1 receptor agonists

Spending on glucagonlike peptide1 receptor agonists, or GLP1s, in the United States increased over 500% from $13.7 billion in 2018 to $71.7 billion in 2023, according to the Journal of the American Heart Association, Although these medications were initially developed to treat Type 2 diabetes, newer indications now include weight management

Starting with Metformin and adding an SGLT2 inhibitor or a GLP-1 agonist allows you to hit your A1C target while protecting your heart and managing weight

Messel An Ancient Greenhouse Ecosystem

A.RovinB

[4] [16] [ | ] =

Discuss risks and benefits with your clinician if considering any non-approved option